We studied the heterogeneity of high-density lipoproteins (HDL) in plasma of 110 subjects, using three different methods: (a) gradient gel electrophoresis (GGE); (b) electroimmunoassay, to measure the concentration of lipoprotein particles containing apoprotein (apo) Al but no apoAll (LP Al); and (c cholesterol esterification rate (FERHDJ in very-low-and low-density lipoprotein-depleted plasma. There were two study groups: patients with hypertension, whose plasma lipid profile was similar to their respective controls, and patients with hypoalphalipoproteinemia (hypoalpha), whose family members served as controls. Values for FERHOL were significantly higher in both risk groups than in their respective controls. LP Al was significantly decreased only in the hypoalpha subjects. Generally, LP Al and FERHDL were inversely related. LP Al correlated strongly with plasma HDL-cholesterol, apo Al, and LP Al/All; FERHDL correlated with those values inversely. LP Al, but not FERHDL,correlated with HDL free cholesterol. On the other hand, FERHDL correlated strongly with plasma concentrations of triglycerides and with the plasma ratio of totat/HDL-cholesterol while LP Al did not. GGE determination of the composition of HDL subspecies showed that both FERHDL and LP Al were significantly related to the content of HDL2b particles: FERHDI_inversely, LP Al directly; the relative amount of HDLC particles correlated only with FERHDL.We conclude that GGE and FERHDLcan be used to quantify both the apparently protective (HDL) and risk-associated (HDL.C) particles, whereas the concentration of LP Al in plasma mainly reflects the concentration of the HDL2 subpopulation. 
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cated that the predictive value of serum concentrations of HDL-cholesterol was about twice that of low-density 11po-protein (LDL) cholesterol (2). However, members of the HDL family of particles differ in size, structure, and function. The relative proportions of various HDL particles might affect the direction of lipid transport between extraand intravascular pools. Subfractionation of HDL by ultracentrifugation indicated that the antiatherogemc properties were mostly associated with the HDL2 subclass (1). 
Materials and Methods Subjects
Two case-control groups were studied. In Prague, 22 volunteers were recruited from apparently healthy laboratory workers and 27 hypertensive patients were recruited from among the outpatients of the Nephrolor Clinic of Institute for Clinical and Experimental Medicine. The age of the subjects ranged from 27 to 70 years.
In Vancouver, we examined 28 patients with primary hypoalpha.
The 31 controls used in this study were relatives of these patients.
All these subjects had HDL cholesterol values >0.9 mmol/L and a wide range of other lipoprotein values, as described earlier (24).
Procedures

Lipid analysis.
Blood was collected into EDTA-contaming tubes after a 12-h overnight fast, placed on ice, and centrifuged within 2 h at 1750g for 10 mm to separate plasma Plasma was analyzed within 48 h if kept on ice, or within 3 months if stored at -20#{176}C, or within 2 years at -70#{176}C. We 
Results
FERHDL, LP Al, Plasma Lipids, and HDL Subclasses
The data obtained from hypertensive and normal subjects of comparable age and body mass index are shown in Table 1 . The most significant differences between these groups were in FERL, plasma total cholesterol, and triglycerides.
The concentration of LP Al was not significantly different between controls and hypertensive patients; however, the control women had significantly higher content of LP Al than did the control men (P <0.01). Values for FERL were also significantly different between the control men and the women (P <0.01). Hypertensive subjects had a tendency toward higher values of HDL3bC and reduced HDL2b, particularly if the ratio of HDLSb,C to HDL2b was used. A similar tendency can be seen in the differences between men and women, namely, lower HDL2b and higher HDL3bC in control men than in control women. 
Correlations
Data analysis of both groups of patients dearly shows an inverse correlation between the plasma concentration of LP Al and FERWL. Despite the weakness of the correlation (Table 3) We conclude, therefore, that FERHJ,L, which reflects the composition of HDL subspecies (specifically, the relative content of HDL2b and HDLSb,C or their interactions), might be a better test than LP Al assay to evaluate the risk of CAD and (or) the effectiveness of treatment for CAD. Assessment of FERunL is a functional test of HDL particle interactions, whereas the LP Al assay mostly reflects only the concentrations of the HDL2 or HDL2b subclasses.
Although, in our opinion,
FERL
yields a useful information about the composition of patients plasma HDL, it is indeed not the ultimate risk indicator; other risk factors, both lipid-related and others, must be assessed in individual patients.
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